Andrew Zolopa
Academic Appointments
- Professor - Med Center Line, Medicine - Infectious Diseases
Key Documents
Contact Information
-
Clinical Offices
Positive Care Clinic 3351 El Camino Real Suite 225 Atherton, CA 94027 Tel Work (650) 723-9001 Fax (650) 568-1708
- Academic Offices
Personal Information Email Tel (650) 723-9062 Tel (650) 723-9001Alternate Contact Connie Goulart Administrative Assistant Email Tel Work (650) 354-8105Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- HIV/AIDS
- Infectious Disease
Administrative Appointments
- Acting Chief of Infectious Diseases, Stanford University, School of Medicine (2008 - present)
Professional Education
| Fellowship: | Stanford University School of Medicine CA (1992) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (1988) |
| Internship: | Santa Clara Valley Medical Center, CA USA (1985) |
| Medical Education: | UCLA School of Medicine CA (1984) |
Community and International Work
- Rwanda/Stanford HIV Mentoring Program, Rwanda Africa
Internet Links
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Dr. Zolopas research applies a variety of clinical epidemiologic methods in an effort to optimize antiretroviral therapy and understand the impact of drug resistance on response to ARV. Areas of focus include the clinical application of resistance testing in optimizing antiretroviral therapy, clinical cohorts, trials of antiretroviral therapies and population-based epidemiologic evaluation of HIV resistance and efficacy of ARV therapy. As the Principal Investigator of Stanford's NIH sponsored AIDS Clinical Trials Unit Dr. Zolopa is engaged in a variety of clinical trials focused on the optimization of ART both in the US and in income limited settings.
More recently studies focused on premature aging in HIV infected popultaions. This work will involve detailed immunologic evaluations and evaluation of end organ complications including heart disease, bone disease, renal disease and neuro-cognitive decline.
Finally, Dr. Zolopa is involved in HIV research in collaboration with the Rwandan Ministry of Health in Africa.
Clinical Trials
- Not Recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
- Recruiting Consent for Use of Stored Patient Specimens for Future Testing
- Recruiting Long-Term Data Collection From Participants in Adult AIDS Clinical Trials
- Not Recruiting HIV Prevention and Care of Psychological Trauma in Vulnerable Rwandan Youth
- Not Recruiting Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Publications
- Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164. J Infect Dis. 2012; (11): 1715-23
- Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-naïve HIV-1-infected patients. J Int AIDS Soc. 2012; (6): 18219
- Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother. 2012; (5): 2305-13
- When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now! Curr HIV/AIDS Rep. 2012; (3): 251-8
- Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS. 2011; (2): 211-20
- Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis. 2010; (6): 814-22
Help